search
Back to results

Danish Osteoporosis Prevention Study

Primary Purpose

Osteoporosis

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Hormone replacement therapy
Sponsored by
University of Aarhus
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Osteoporosis focused on measuring Fracture, Osteoporosis, Bone mineral density, Hormone replacement therapy, Estrogen, Breast cancer

Eligibility Criteria

45 Years - 58 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Women aged 45-58 years with an intact uterus Three to 24 month past last menstrual bleeding Hysterectomised women aged 45-52 years and having elevated FSH Exclusion Criteria: Metaboliv bone disease including osteoporosis defined as non-traumatic vertebral fractures on X-ray Current estrogen use or estrogen use within the past three month Current or past treatment with glucocorticoids for more than 6 month Current or past malignancy Newly diagnosed or uncontrolled chronic disease Alcohol or drug addiction

Sites / Locations

  • The Osteoporosis Clinic, Aarhus Sygehus

Outcomes

Primary Outcome Measures

Fracture
Bone mineral density

Secondary Outcome Measures

Breast cancer
Menopausal symptoms

Full Information

First Posted
November 10, 2005
Last Updated
September 3, 2009
Sponsor
University of Aarhus
Collaborators
Karen Elise Jensen Foundation, Novo Nordisk A/S, LEO Pharma, Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00252408
Brief Title
Danish Osteoporosis Prevention Study
Official Title
Danish Osteoporosis Prevention Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
October 1990 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2003 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of Aarhus
Collaborators
Karen Elise Jensen Foundation, Novo Nordisk A/S, LEO Pharma, Novartis

4. Oversight

5. Study Description

Brief Summary
Hypothesis: Use of hormone replacement therapy (HRT) decreases the incidence of fractures in early postmenopausal women. The project was initiated in 1990, and the inclusion ended in 1993. A total of 2,016 early postmenopausal women were divided into two groups: The first group accepted randomisation to HRT or not, and the second group was allowed to choose HRT or not. The study was not blinded. Main measurements were fracture risk over 20 years, changes in bone mineral density over 20 years, and side effects, mainly breast cancer.
Detailed Description
Aim: To study the ability of hormone replacement early after menopause on risk of fractures and changes in bone mineral density, and side effects. The project was designed as a comprehensive cohort trial. One group accepted randomisation, and was randomised to hormone replacement therapy (HRT) or not (no placebo used). 502 were randomised to HRT, and 504 were randomised to no HRT) One group was allowed to choose HRT or not. A total of 221 chose HRT, and 789 chose no HRT. First line HRT was oral sequential oestradiol/norethisterone in women with intact uterus and oral continuous oestradiol in hysterectomised women. The study was initiated in 1990, and inclusion ended in 1993.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis
Keywords
Fracture, Osteoporosis, Bone mineral density, Hormone replacement therapy, Estrogen, Breast cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2000 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Hormone replacement therapy
Primary Outcome Measure Information:
Title
Fracture
Title
Bone mineral density
Secondary Outcome Measure Information:
Title
Breast cancer
Title
Menopausal symptoms

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
58 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women aged 45-58 years with an intact uterus Three to 24 month past last menstrual bleeding Hysterectomised women aged 45-52 years and having elevated FSH Exclusion Criteria: Metaboliv bone disease including osteoporosis defined as non-traumatic vertebral fractures on X-ray Current estrogen use or estrogen use within the past three month Current or past treatment with glucocorticoids for more than 6 month Current or past malignancy Newly diagnosed or uncontrolled chronic disease Alcohol or drug addiction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leif Mosekilde, Professor MD DrMedSc
Organizational Affiliation
department of Endocrinology and Metabolism C, Aarhus University Hospital, Denmark
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jens Erik Beck Jensen, MD PhD
Organizational Affiliation
The Osteoporosis Clinic, Hvidovre Hospital, Copenhagen
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Peder Charles, MD DrMedSc
Organizational Affiliation
Department of Endocrinology and Metabolism C, Aarhus University Hospital, Denmark
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Stig Pors Nielsen, MD DrMedSc
Organizational Affiliation
Department of Clinical Physiology and Nuclear Medicine, Hillerød Hospital, Hillerød, Denmark
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Henning Beck Nielsen, MD DrMedSc
Organizational Affiliation
Odense University Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kim Brixen, MD PhD
Organizational Affiliation
Odense University Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ole Helmer Sørensen, MD DrMedSc
Organizational Affiliation
The Osteoporosis Clinic, Hvidovre Hospital, Copenhagen, Denmark
Official's Role
Study Director
Facility Information:
Facility Name
The Osteoporosis Clinic, Aarhus Sygehus
City
Aarhus
ZIP/Postal Code
DK-8000
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
11063900
Citation
Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P, Hermann AP, Gram J, Hansen TB, Abrahamsen B, Ebbesen EN, Stilgren L, Jensen LB, Brot C, Hansen B, Tofteng CL, Eiken P, Kolthoff N. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas. 2000 Oct 31;36(3):181-93. doi: 10.1016/s0378-5122(00)00158-4.
Results Reference
result
PubMed Identifier
24446656
Citation
Torekov SS, Harslof T, Rejnmark L, Eiken P, Jensen JB, Herman AP, Hansen T, Pedersen O, Holst JJ, Langdahl BL. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014 Apr;99(4):E729-33. doi: 10.1210/jc.2013-3766. Epub 2014 Jan 21.
Results Reference
derived
PubMed Identifier
23048011
Citation
Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Kober L, Jensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9;345:e6409. doi: 10.1136/bmj.e6409.
Results Reference
derived

Learn more about this trial

Danish Osteoporosis Prevention Study

We'll reach out to this number within 24 hrs